The less and non-aggressive breast cancer cells, SKBr3 and MCF-7 respectively displayed less dependency on matrix stiffness.
Compared with WB, the WBΔ3446 and WBΔ3446Δ3986 mutants respectively displayed 36%and65%5% yield enhancement of erythromycin A, following significantly elevated transcription of eryAI and ermE.
E1.NH2 and E1.NHAc exhibited only minor deviations from ideal structures and, respectively, displayed a narrow distribution; while E1.N(Gly)OH had a much broader distribution centered around 14±3 glycidol substituents.
Dgn-2 and Dgn-5 bearing o-nitrophenyl and o-cyanophenyl R moieties respectively, displayed impressive anti-proliferative activity against all the tested human cancer cell lines with IC50 values ranging from 5.77 to 9.44 μM.
On two cell lines, the bufalin-3-piperidinyl-4-carboxylate compound 2 (IC50 values on HeLa and A549 cell lines were 0.76 nM and 0.34 nM, respectively) displayed a significant cytotoxic potency compared to the parent compound bufalin.
Out of six, two and three C57BL/6 mice orally and nasally inoculated with the recombinant bacteria, respectively, displayed anti-EDIII antibody responses higher than that obtained in the mouse group intraperitoneally (i.p).
Among them, compounds 8q, 8t, and 8w with excellent Chk1 inhibitory activities (IC50 values of 4.05, 6.23, and 2.33 nM, respectively) displayed strong synergistic effects with melphalan, a DNA-damaging agent in the cell-based assay.
Compounds 9e and 9j (IC50.05757 and 0.072 μM, respectively) displayed the greatest cytotoxicity against the multidrug-resistant (MDR) KBvin cell line and merit further development into preclinical and clinical drug candidates for treating cancer including MDR phenotype.
Moreover, compounds 3b d (with EC50 values of 13.191, 13.441, and 13.191 g ai/ha, respectively) displayed more promising herbicidal activity against E. crus-galli than sulfentrazone (a commercial herbicide with an EC50 value of 15.606 g ai/ha).
